Hemophilia groups warned of 5 deaths among patients taking Roche’s big new blockbuster Hemlibra
The Hemophilia Federation of America has put out a statement noting that Roche alerted them of the deaths of 5 patients who were taking their new drug Hemlibra, calculated to be the biggest single drug launch of the year. And according to Roche, the alert followed the death of two patients earlier this year, which they just learned about.
According to the statement, Roche’s Genentech informed them of the deaths Monday — adding 4 fatalities to the 1 death already reported early last year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.